Global Emerging Markets, a $3.4bn, alternative investment group, agreed to invest $90m in NuView Life Sciences, a clinical stage, precision oncology company. "This agreement with GEM helps to secure the funding for continued growth and development of NuView’s NV-VPAC1(TM) portfolio. As we focus on moving our in vitro cancer diagnostics into the marketplace, we can simultaneously restart our in vivo diagnostics and Theranostic programs forward," Paul Crowe, NuView Chairman and CEO.